<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615896</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1037</org_study_id>
    <nct_id>NCT05615896</nct_id>
  </id_info>
  <brief_title>Data Collection With the P200TE and P200TxE</brief_title>
  <official_title>Data Collection With the P200TE and P200TxE in Diseased Eyes for Clinical Developments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to collect OCT scans on a modified P200TxE and P200TE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study is no longer required.&#xD;
  </why_stopped>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Actual">June 17, 2022</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of images</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint will be the collection of OCT scans on the P200TE and P200TxE devices. The scans will be used by R&amp;D for development of a de-noising algorithm as well as other possible developments.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Retinal Disease</condition>
  <arm_group>
    <arm_group_label>P200TxE Device First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>P200TE Device First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imaging Session</intervention_name>
    <description>Various scans will be captured on both devices</description>
    <arm_group_label>P200TE Device First</arm_group_label>
    <arm_group_label>P200TxE Device First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Male or female volunteers 22 years of age or older who have full legal capacity to&#xD;
             volunteer on the date the informed consent is signed;&#xD;
&#xD;
          -  Volunteers who can follow the instructions by the clinical staff at the clinical site;&#xD;
&#xD;
          -  Volunteers who agree to participate;&#xD;
&#xD;
          -  Volunteers who have been diagnosed with retina pathology with intra-retinal and/or&#xD;
             subretinal fluid present in the posterior pole region.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers unable to tolerate ophthalmic imaging;&#xD;
&#xD;
          -  Volunteers with ocular media not sufficiently clear to obtain acceptable OCT images.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retina Consultants of Texas Research Centers</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

